Transanal irrigation for low anterior resection syndrome: a systematic review and narrative synthesis with emphasis on nurse-led implementation.

Minerva Gastroenterol (Torino)Feb 17, 2026 (epub)
Clinical ResearchGastroenterology

Diego Lopane, Filippo Bianchi, Daniela Cattani et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and narrative synthesis examined transanal irrigation (TAI) for adults with low anterior resection syndrome after sphincter-preserving rectal surgery, including evidence on nurse-led implementation. Four studies—two randomised trials, one prospective observational study and one mixed-methods study—included 332 patients. Across studies, LARS scores fell by 8.5-23 points, and 68-82% of patients achieved clinically meaningful improvement (≥4 points MCID). No serious adverse events were reported. Adherence was higher in studies with structured nurse-led education and follow-up, although the evidence was heterogeneous and no formal meta-analysis was conducted.

Key findings

  • Across studies, TAI reduced LARS scores by 8.5-23 points; 68-82% of patients achieved clinically meaningful improvement (≥4 points MCID).
  • Minor adverse events occurred in 1.2% of patients (3/242); no serious adverse events were reported.
  • Adherence was 85-100% in studies with structured nurse-led support, versus 60-78% with minimal-to-moderate nursing involvement.

Why it matters

LARS can substantially affect quality of life after rectal surgery, and this review suggests TAI may improve symptoms with few reported adverse events. The higher adherence observed alongside structured nursing support highlights implementation as a potentially important part of care. However, evidence certainty varied, and the findings do not establish long-term effectiveness or a standard delivery approach.

What to keep in mind

Only four heterogeneous studies were included, with a total of 332 patients and median follow-up of 4 months. No formal meta-analysis was possible; certainty ranged from very low to moderate.

Source

Published in Minerva Gastroenterol (Torino). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.